NEW YORK, March 29, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Grocery Outlet Holding Corp.

NEWPORT NEWS, Va., March 29, 2025 ( GLOBE NEWSWIRE ) -- HII HII hosted commencement exercises today, celebrating 77 graduates of the company's Newport News Shipbuilding Apprentice School. The ceremony was held at Liberty Live Church in Hampton. Virginia State Sen.

Elon Musk sounds the alarm on Western population decline, fearing for civilization's future. The Tesla CEO highlights America's record-low birth rates, alongside South Korea's drastic drop. Feel unsure about the market's next move?

Mark Cuban warns against replacing human skills with AI, stressing it should augment, not replace. Over-reliance on AI could leave companies trailing, Cuban advises embracing AI as a competitive tool. Feel unsure about the market's next move?

Iran signals openness to indirect talks with the U.S., rejecting direct negotiations under sanctions and military threats. Trump sets a two-month deadline for negotiations, with military strikes on Iran's nuclear sites looming if talks fail. Feel unsure about the market's next move?

Ray Dalio equates market timing with Olympic-level difficulty, warning investors of its complexity. Billionaire investor advocates for low-cost index funds over risky market timing strategies. Markets are swinging wildly, but for Matt Maley, it's just another opportunity to trade.

I'm using ETFs to get AI exposure in my portfolio, and here are three of my favorites.

- Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction ( p=0.001 ) , assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.

Bagsværd, Denmark, 29 March 2025 - Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ( oral semaglutide ) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular ...